NCT02624219View on ClinicalTrials.gov

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions
Avian InfluenzaInfluenza
Interventions
DRUG

AS03

AS03 oil-in-water emulsion adjuvant.

DRUG

MF59 adjuvant

Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

BIOLOGICAL

Monovalent Influenza A/H5N8 vaccine

Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Trial Locations (4)

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

45229-3039

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02624219 - H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults | Biotech Hunter | Biotech Hunter